Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies
Cells · 07.06.2024 · 13 (12) · 998
DOI: 10.3390/cells13120998 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 07.06.2024. Verfasst von Esther Ter Linden und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. Hauptthemen laut MEDLINE: Glioblastoma, Blood-Brain Barrier, Drug Delivery Systems, Brain Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society, Hersenstichting, Spinza grand by the Institute for Chemical Immunology.
Abstract (Originalsprache)
The world of cancer treatment is evolving rapidly and has improved the prospects of many cancer patients. Yet, there are still many cancers where treatment prospects have not (or hardly) improved. Glioblastoma is the most common malignant primary brain tumor, and even though it is sensitive to many chemotherapeutics when tested under laboratory conditions, its clinical prospects are still very poor. The blood–brain barrier (BBB) is considered at least partly responsible for the high failure rate of many promising treatment strategies. We describe the workings of the BBB during healthy conditions and within the glioblastoma environment. How the BBB acts as a barrier for therapeutic options is described as well as various approaches developed and tested for passing or opening the BBB, with the ultimate aim to allow access to brain tumors and improve patient perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
- Department of Neurosurgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
- Department of Neurosurgery, Haaglanden Medical Center, 2512 VA The Hague, The Netherlands.
ORCID-Profile: Erik R Abels
Förderung
- Dutch Cancer Society
- Hersenstichting
- Spinza grand by the Institute for Chemical Immunology
- NWO Gravitation project funded by the Ministry of Education, Culture and Science of the Neth-erlands
- Institute for Chemical Immunology
- Ministry of Education, Culture and Science of the Netherlands
Zitieren
APA
Ter Linden, E., Abels, E. R., van Solinge, T. S., Neefjes, J., & Broekman, M. L. D. (2024). Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies. Cells, 13(12), 998. https://doi.org/10.3390/cells13120998
Vancouver
Ter Linden E, Abels ER, van Solinge TS, Neefjes J, Broekman MLD. Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies. Cells. 2024;13(12):998. doi:10.3390/cells13120998
BibTeX
@article{TerLinden2024,
author = {Ter Linden, Esther and Abels, Erik R and van Solinge, Thomas S and Neefjes, Jacques and Broekman, Marike L D},
title = {Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies},
journal = {Cells},
year = {2024},
volume = {13},
number = {12},
pages = {998},
doi = {10.3390/cells13120998}
}
EUVIMED